PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection

• Status: Completed
• Trial end date: 2018-05-31
• Target enrollment: 0
• Participant gender: All

Summary

This clinical trial studies positron emission tomography (PET)/computed tomography (CT) in diagnosing patients with liver cancer undergoing surgical resection. Diagnostic procedures, such as fluorine-18 fluoromethylcholine PET/CT, may help find and diagnose liver cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Queen's Medical Centre
• Collaborators: National Cancer Institute (NCI); National Institutes of Health (NIH); University of Hawaii Cancer Research Center
• Treatments: Choline

Criteria

Inclusion Criteria:

• Liver tumor diagnosed histologically as HCC or suspected of being HCC in association with serum alpha-fetoprotein level > 200 or tumor mass with characteristics of malignancy on diagnostic imaging

• Under the care of a surgical attending

• Deemed a surgical candidate and has agreed to surgery to remove a portion of the liver containing tumor

• Child-Pugh A/B

Exclusion Criteria:

• Weight > 350 lbs

• Pregnant or lactating female, a serum pregnancy test will be performed within 2 weeks or less before the date of the FCH PET/CT scan in all women capable of becoming pregnant

• Serious underlying medical condition that would impair patient's ability to tolerate the imaging procedure

• Concurrent treatment with chemotherapy, molecule-selective, biological, or radiotherapeutic agent